Platelet transfusion refractoriness

From WikiMD.com Medical Encyclopedia

A condition where patients do not respond adequately to platelet transfusions


Platelet Transfusion Refractoriness[edit | edit source]

Platelet transfusion refractoriness is a clinical condition in which patients exhibit an inadequate response to platelet transfusions. This condition is of particular concern in patients who require frequent platelet transfusions, such as those undergoing treatment for hematological malignancies or those with severe thrombocytopenia.

Causes[edit | edit source]

Platelet transfusion refractoriness can be caused by a variety of factors, which are generally categorized into immune and non-immune causes.

Immune Causes[edit | edit source]

Immune-mediated refractoriness is often due to the development of alloantibodies against human leukocyte antigens (HLA) or human platelet antigens (HPA). These antibodies can develop after exposure to foreign antigens through previous transfusions, pregnancy, or transplantation. The presence of these antibodies leads to rapid destruction of transfused platelets, resulting in poor post-transfusion platelet increments.

Non-Immune Causes[edit | edit source]

Non-immune causes of refractoriness include factors such as splenomegaly, fever, sepsis, disseminated intravascular coagulation (DIC), and the use of certain medications. These conditions can lead to increased platelet consumption or destruction, independent of immune mechanisms.

Diagnosis[edit | edit source]

The diagnosis of platelet transfusion refractoriness is typically made by measuring the post-transfusion platelet count increment. A corrected count increment (CCI) of less than 5,000 to 7,500 per microliter at 10 to 60 minutes post-transfusion on at least two occasions is indicative of refractoriness.

Management[edit | edit source]

Management of platelet transfusion refractoriness involves identifying and addressing the underlying cause. For immune-mediated refractoriness, strategies may include:

For non-immune causes, treatment focuses on managing the underlying condition, such as controlling infections or discontinuing medications that may contribute to platelet destruction.

Prevention[edit | edit source]

Preventive strategies for platelet transfusion refractoriness include:

  • Limiting exposure to allogeneic platelets by using leukoreduced blood products
  • Using single-donor apheresis platelets instead of pooled random donor platelets
  • Implementing transfusion protocols that minimize unnecessary platelet transfusions

Related Pages[edit | edit source]

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD